Lucid Diagnostics (NASDAQ:LUCD) Receives “Overweight” Rating from Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Lucid Diagnostics (NASDAQ:LUCD) in a research report report published on Wednesday,Benzinga reports. They currently have a $2.00 target price on the stock.

Several other research firms also recently issued reports on LUCD. Ascendiant Capital Markets cut their price objective on Lucid Diagnostics from $7.25 to $7.00 and set a “buy” rating on the stock in a report on Monday, December 9th. Needham & Company LLC lifted their price objective on shares of Lucid Diagnostics from $2.50 to $3.00 and gave the stock a “buy” rating in a research report on Monday. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $3.40.

Lucid Diagnostics Price Performance

NASDAQ LUCD opened at $1.55 on Wednesday. The company has a market capitalization of $91.98 million, a P/E ratio of -1.36 and a beta of 1.34. Lucid Diagnostics has a 12 month low of $0.63 and a 12 month high of $1.63. The company’s 50 day simple moving average is $1.24 and its 200 day simple moving average is $1.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. LPL Financial LLC boosted its stake in shares of Lucid Diagnostics by 29.1% during the 4th quarter. LPL Financial LLC now owns 53,391 shares of the company’s stock valued at $44,000 after buying an additional 12,035 shares during the period. Lido Advisors LLC boosted its position in Lucid Diagnostics by 40.0% during the fourth quarter. Lido Advisors LLC now owns 140,016 shares of the company’s stock valued at $115,000 after purchasing an additional 40,000 shares during the last quarter. Geode Capital Management LLC grew its stake in Lucid Diagnostics by 30.9% in the fourth quarter. Geode Capital Management LLC now owns 279,504 shares of the company’s stock valued at $229,000 after purchasing an additional 65,964 shares in the last quarter. Sunbelt Securities Inc. acquired a new position in Lucid Diagnostics in the 4th quarter worth about $67,000. Finally, Citadel Advisors LLC purchased a new stake in shares of Lucid Diagnostics during the 4th quarter worth about $98,000. 74.01% of the stock is owned by hedge funds and other institutional investors.

Lucid Diagnostics Company Profile

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.